MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. PDEX
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Pro-Dex (PDEX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Pro-Dex
NasdaqCM•Healthcare•Medical Instruments & Supplies
$62.81+2.97(0.05%)Market closed
Market Cap
$221.71M
P/E
16.2x
P/S
2.9x
P/B
4.7x

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

A

How this company scores

ExcellentMetricSide Score: 86/100

Strongest: Profitability (25/25); weakest: Cash & Earnings Quality (14/25).

Profitability25/25
Growth25/25
Balance Sheet & Red Flags22/25
Cash & Earnings Quality14/25
Strengths
Growing revenueStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 16.2x5y range 0.0x – 32.3x
P/E 16.2x · above its 20-quarter median

Currently above its 20-quarter median.

P/S · 2.9x5y range 0.0x – 2.9x
P/S 2.9x · above its 20-quarter median

Currently above its 20-quarter median.

P/B · 4.7x5y range 0.0x – 4.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.1x) — earnings may be inflated by non-cash items or aggressive accounting.

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.

Price & Volume
Market Cap $221.71M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$77.55M
7Q
Q. Revenue
$20.41M
7Q
TTM EBITDA
$14.38M
21%
TTM Op. Income
$12.99M
22%
Q. Op. Income
$3.53M
163%
TTM Net Income
$13.66M
4Q
Q. Net Income
$2.86M
139%
EPS
$0.895
152%
Shares Out.
$3.19M
4Q
$77.55M in TTM revenue grew 16.5% YoY, reaching $20.41M last quarter. TTM EBITDA of $14.38M and TTM operating income of $12.99M show growth is flowing through to the bottom line. TTM net income of $13.66M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
34.8%
74%
EBITDA Margin
19.3%
103%
Op. Margin
17.3%
125%
Net Margin
14.0%
105%
Op. margin of 17.3% is up 9.6% YoY — cost efficiency is improving. Net margin at 14.0% and gross margin of 34.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 125% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
16.2x
3Q
P/S Ratio
2.9x
3Q
P/B Ratio
4.7x
3Q
At 16.2x P/E, the stock trades within typical market levels. P/S of 2.9x and P/B of 4.7x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 3 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$74.51M
22%
Cash
$8.19M
3Q
Long-Term Debt
$17.51M
Book Value
$47.63M
7Q
D/E Ratio
0.4
Debt/EBITDA
4.5
52%
With $74.51M in assets and $17.51M in long-term debt, D/E is 0.4and book value is $47.63M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 0% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$-273,000
2Q
TTM Free Cash Flow
$6.76M
338%
FCF Margin
8.7%
305%
FCF / Net Income
0.5
257%
TTM FCF of $6.76M on $-273,000 in operating cash flow. The FCF / Net Income ratio of 0.5x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 338% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 4.7x
· above its 20-quarter median

Currently above its 20-quarter median.